Sara Tolaney· @stolaney1 · X·· 2 days agoScore90
Body
HORIZON-Breast06: Trastuzumab rezetecan in metastatic HER2low breast cancer
n=551
PFS chemo-naive: 16.6 vs 6.8 mo HR 0.25
PFS consistent in HR+ vs HR- (HR 0.34 and HR 0.24)
OS immature
ILD 2.5%
@OncoAlert #ESMO2026
522 views · 9 likes · 9 reposts · 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Sara Tolaney · x.com